Chemo-Resistant Pancreatic Tumor Liquefies and Drains Several Months after Receiving Proprietary Intratumoral EpCAM/CD3 Vaccine

Data ReadoutpositiveEpCAM/CD3 vaccinegemcitabinePositive

AI Analysis

Summary

A peer-reviewed case report from ICCA CancerCare documents a 90% volume reduction in a chemo-resistant pancreatic tumor following treatment with a proprietary intratumoral EpCAM/CD3 vaccine, accompanied by extensive necrosis without surgery or full-dose chemotherapy.

Outcome Details

Case report documents 90% tumor volume reduction with extensive necrosis in chemo-resistant pancreatic tumor after intratumoral EpCAM/CD3 vaccine treatment, achieved without surgery or full-dose chemotherapy after gemcitabine failure

Importance:5/10

Sentiment:

0.75

pancreatic cancerimmunotherapyvaccinecase reporttumor responseintratumoral

Read the original article

Published by PR Newswire Pharma on September 7, 2026 4:55 PM

Read Original